Abbott Labs: Q4 EPS up 15%

(CercleFinance.com) - Abbott Laboratories reports Q4 2023 adjusted EPS of $1.
19, up 15.5% y-o-y, on revenues that rose 1.5% to $10.2bn.

On an organic basis and excluding sales linked to Covid-19 tests, the healthcare group's quarterly sales rose by 11%, in particular boosted by the medical devices (+15.4%) and nutrition (+13.9%) divisions.

With FY 2023 adjusted EPS of $4.44 and organic sales growth (excluding Covid-19-related revenues) of 11.6%, Abbott expects 2024 target ranges of $4.50-4.70 and 8%-10% respectively.


Copyright (c) 2024 CercleFinance.com. All rights reserved.